AZN

AstraZenecaF

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

25%

Probability

Target price

$123.69

Analysis reference price unavailable

Analysis 2026-01-24 · RankAlpha Sentiment AI

Most likely

Base case

60%

Probability

Target price

$97.65

Analysis reference price unavailable

Analysis 2026-01-24 · RankAlpha Sentiment AI

B-

Bear case

15%

Probability

Target price

$79.98

Analysis reference price unavailable

Analysis 2026-01-24 · RankAlpha Sentiment AI

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-01-24

AI commentary

Consensus is mildly constructive with median targets near our base case; near-term focus is the FY2025 print, while longer-term sentiment hinges on late-stage pipeline outcomes.

RankAlpha Sentiment AI - 2026-01-24

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-02-10eventFY2025 earnings releaseMedium impact

Full-year 2025 results and guidance update; historically a primary re-pricing event for the stock.

2026-04-24catalystNear-term capital-allocation updateMedium impact

Potential buyback/dividend commentary or modest buyback tranche announcement that could support the share price.

2027-01-24catalystLate-stage trial readouts / regulatory milestonesHigh impact

Clinical or regulatory outcomes for late-stage assets that could drive material upside or downside over a longer horizon.

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-01-24 • Updated nightlySource: Internal modelMethodology